Skip to main content

Table 4 Descriptive analysis of baseline clinical and therapeutical variables : monoinfected vs coinfected patients with HCV genotype 3.

From: Sustained virological response to peginterferon therapy in patients infected with HCV (genotypes 2 and 3), with or without HIV

Variables HIV- (n = 181) HIV+ (n = 72) Odds Ratio
(95% IC)
p-value
Cirrhosis, % (n) 66% (12) 30.6% (22) 6.1 (2.8-13.6) <0.0001
HCV-RNA >500.000 IU/ml, % (n) 46.9% (84) 31.9% (23) 0.53 (0.3-0.9) 0.03
PegIFN alfa-2b, % (n) 23.2% (42) 29.2% (21) 1.36 (0.7-2.5) 0.32
PegIFN reduction, % (n) 11.6% (21) 5.6% (4) 0.45 (0.13-1.3) 0.15
Stop PegIFN % (n) 16.6% (30) 31.9% (23) 2.35 (1.24-4.44) 0.007
RBV reduction, % (n) 12.2% (22) 13.9% (10) 1.6 (0.5-2.6) 0.71
Stop RBV, % (n) 9.4% (17) 29.2% (21) 3.95 (1.93-8.17) <0.0001
Male gender, % (n) 76.8% (139) 81.9% (59) 1.37 (0.7-2.8) 0.37
Age >45 years, % (n) 27.6% (50) 48.6% (35) 2.4 (1.4-4.4) 0.001
PLT <130,000 cell/mm3, % (n) 8.3% (15) 33.3% (24) 5.4 (2.7-11.5) <0.0001
Variables HIV- (n = 181) HIV+ (n = 72)   p -value
ALT, mean (DS) 139.7 (118.6) 117.6 (75.5)   0.26
AST, mean (DS) 78.7 (70.6) 76.5 (49.9)   0.69
BMI, mean (DS) 25.1 (3.7) 23.6 (3.2)   0.006
Cholesterol, mean (DS) 152.5 (39.3) 148.9 (40)   0.52
Triglycerids, mean (DS) 82.3 (45) 108.5 (61.8)   0.0004
Glycemia, mean (DS) 93.6 (21.9) 90.2 (12.1)   0.39
Hb, mean (DS) 15.3 (1.5) 14.5 (2.1)   0.003
PT, mean (DS) 102 (11.6) 101 (12.6)   0.96
Neutrophils, mean (DS) 3597 (1327) 3118 (1364)   0.004
Weeks of treatment, mean (DS) 20.7 (9.1) 40.7 (17.8)   <0.0001
Bilirubine, mean (DS) 0.82 (0.45) 1.55 (1.48)   0.0002
Albumine, mean (DS) 4.63 (3.13) 4.39 (0.47)   0.47
SVR rate, ITT analysis HIV- (n = 181) HIV+ (n = 72) Odds Ratio
(95% IC)
p -value
SVR, % (n) 76.8 % (139) 68.1 % (72) 0.65 (0.3-1.2) 1.15
SVR rate, PP analysis HIV- (n = 151) HIV+ (n = 49) Odds Ratio
(95% IC)
p -value
SVR, % (n) 83.4 % (126) 85.7 % (42) 1.19 (0.5-3.1) 0.7
  1. PLT, platelets; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, Body Mass Index; Hb, hemoglobin; PT, prothrombin time.